Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Korean J Hematol. 1999 May;34(2):344-348. Korean. Case Report.
Lee SH , Choi SY , Park TG , Lee DH , Kim HS , Lee JS , Lee CW , Cheong SP , Lee KH , Hyun MS .
Department of Internal Medicine, Pohang St. Mary's Hospital1, Pohang, Korea.
Department of Internal Medicine, College of Medicine, Yeung Nam University, Taegu, Korea.

Prolymphocytic leukemia (PL) is usually derived from B cells and shares some features with chronic lymphocytic leukemia (CLL), but it is clearly a distinct entity and defined to have more than 55% prolymphocytes. Chronic lymphocytic leukemia/prolymphocytic leukemia (CLL/PL) is a mixed type of CLL and is defined to have 11~55% prolymphocytes with intermediate features between CLL and PL. We experienced two different cases of leukemia PL and CLL/PL. On physical examination, PL (stage II, B) patient showed multiple cervical lymph node enlargement and 5cm sized splenomegaly and hepatomegaly. But CLL/PL (stage III, C) patient showed 10cm sized splenomegaly and no lymph node enlargement. On immunological phenotyping, surface markers showed 72% CD5 (+), 85% CD19 (+), and 40% SmIg (+) in PL patient and 3% CD5 (+), 90% CD19 (+) and SmIg (-) in CLL/PL patient. PL patient was refractory to chlorambucil and prednisolone chemotherapy and showed poor prognosis. CLL/PL patient did not show remarkable response to chlorambucil and prednisolone therapy.

Copyright © 2019. Korean Association of Medical Journal Editors.